The efficacy analysis of immunotherapy rechallenge after progression from first-line chemo-immunotherapy in advanced non-small cell lung cancer | Synapse
March 3, 2026Open Access
The efficacy analysis of immunotherapy rechallenge after progression from first-line chemo-immunotherapy in advanced non-small cell lung cancer
Key Points
Immunotherapy rechallenge may maintain efficacy after progression from first-line chemo-immunotherapy in advanced non-small cell lung cancer.
Evidence shows promising outcomes with better disease control compared to traditional approaches.
Analysis included patients who experienced initial progression but later responded to rechallenge with immunotherapy.
May enable new treatment pathways for patients failing first-line chemo-immunotherapy, though further validation is needed.